Literature DB >> 24485057

Update on romiplostim and eltrombopag indirect comparison.

Katy Cooper1, James Matcham2, Kawitha Helme3, Ron Akehurst1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24485057     DOI： 10.1017/S0266462313000767

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN： 0266-4623            Impact factor:   2.188


× No keyword cloud information.
  6 in total

Review 1.  Evidence-based management of immune thrombocytopenia: ASH guideline update.

Authors:  Cindy E Neunert; Nichola Cooper
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

3.  Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.

Authors:  Jiaxing Zhang; Yi Liang; Yuan Ai; Xiaosi Li; Juan Xie; Youping Li; Wenyi Zheng; Rui He
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

4.  Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.

Authors:  Maria L Lozano; Maria E Mingot-Castellano; María M Perera; Isidro Jarque; Rosa M Campos-Alvarez; Tomás J González-López; Gonzalo Carreño-Tarragona; Nuria Bermejo; Maria F Lopez-Fernandez; Aurora de Andrés; David Valcarcel; Luis F Casado-Montero; Maria T Alvarez-Roman; María I Orts; Silvana Novelli; Nuria Revilla; Jose R González-Porras; Estefanía Bolaños; Manuel A Rodríguez-López; Elisa Orna-Montero; Vicente Vicente
Journal:  Sci Rep       Date:  2019-11-13       Impact factor: 4.379

Review 5.  Management of immune thrombocytopenia: 2022 update of Korean experts recommendations.

Authors:  Young Hoon Park; Dae-Young Kim; Seongkoo Kim; Young Bae Choi; Dong-Yeop Shin; Jin Seok Kim; Won Sik Lee; Yeung-Chul Mun; Jun Ho Jang; Jong Wook Lee; Hoon Kook; On Behalf Of Korean Aplastic Anemia Working Party
Journal:  Blood Res       Date:  2022-03-31

Review 6.  Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.

Authors:  Jiaxing Zhang; Yi Liang; Yuan Ai; Xiaosi Li; Juan Xie; Youping Li; Wenyi Zheng; Rui He
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.